Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Therapeutic Advances in Chronic Disease
|
March 4, 2014
Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance
Kathleen Mullane
The New England Journal of Medicine
|
August 15, 2003
Pseudo-SARS
Stuart Johnson, Meenal Patel, Kathleen Mullane
Journal of Cardiac Failure
|
May 20, 2017
Acute Myocarditis Secondary to Reactivated Chromosomally-Integrated Human Herpesvirus 6
Ann B Nguyen, Ben Bow Chung, Gabriel Sayer, et al.
Laboratory Medicine
|
September 21, 2020
Cording in Disseminated Mycobacterium chelonae Infection in an Immunocompromised Patient
Gregory Olson, Moira C McNulty, Kathleen Mullane, et al.
JCO Oncology Practice
|
August 22, 2020
Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program
Benjamin A Derman, Zachary Schlei, Sandeep Parsad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 4, 2012
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection
Michelle M Nerandzic, Kathleen Mullane, Mark A Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin
Oliver A Cornely, Mark A Miller, Bruno Fantin, et al.
BMJ Open Gastroenterology
|
October 14, 2015
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
Karl Weiss, Thomas Louie, Mark A Miller, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 14, 2015
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
Robert Orenstein, Erik Dubberke, Robert Hardi, et al.
BMC Infectious Diseases
|
March 28, 2013
Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy
Mark A Miller, Thomas Louie, Kathleen Mullane, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Therapeutic Advances in Chronic Disease
|
March 4, 2014
Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance
Kathleen Mullane
The New England Journal of Medicine
|
August 15, 2003
Pseudo-SARS
Stuart Johnson, Meenal Patel, Kathleen Mullane
Journal of Cardiac Failure
|
May 20, 2017
Acute Myocarditis Secondary to Reactivated Chromosomally-Integrated Human Herpesvirus 6
Ann B Nguyen, Ben Bow Chung, Gabriel Sayer, et al.
Laboratory Medicine
|
September 21, 2020
Cording in Disseminated Mycobacterium chelonae Infection in an Immunocompromised Patient
Gregory Olson, Moira C McNulty, Kathleen Mullane, et al.
JCO Oncology Practice
|
August 22, 2020
Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program
Benjamin A Derman, Zachary Schlei, Sandeep Parsad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 4, 2012
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection
Michelle M Nerandzic, Kathleen Mullane, Mark A Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin
Oliver A Cornely, Mark A Miller, Bruno Fantin, et al.
BMJ Open Gastroenterology
|
October 14, 2015
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
Karl Weiss, Thomas Louie, Mark A Miller, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 14, 2015
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
Robert Orenstein, Erik Dubberke, Robert Hardi, et al.
BMC Infectious Diseases
|
March 28, 2013
Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy
Mark A Miller, Thomas Louie, Kathleen Mullane, et al.
Page
of 2